SCHEMBL6660360

SCHEMBL6660360

CCC1CC(=O)N(Cc2ccccc2NC(=O)c2ccccn2)N=C1c1ccc(OC)c(OC)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 8/20 0.46
PDE4B Q07343 8/20 0.46
PDE4C Q08493 8/20 0.46
PDE4D Q08499 8/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
KDM4E B2RXH2 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
GRM5 P41594 2/20 0.45
TLR7 Q9NYK1 1/20 0.43
MAPT P10636 2/20 0.43
TP53 P04637 1/20 0.43
KMT2A Q03164 1/20 0.43
CD274 Q9NZQ7 3/20 0.42
PDE3B Q13370 1/20 0.41
PDE3A Q14432 1/20 0.41
PDCD1 Q15116 1/20 0.41
CHEK1 O14757 1/20 0.41
CFTR P13569 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6658965 0.93 PDE4D (0.45) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL6658111 0.92 KMT2A (0.44) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL6675577 0.89 MAPT (0.42) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL6656681 0.89 PDE4D (0.43) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL6843968 0.89 PDE4D (0.44) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL6656461 0.89 SMN1; SMN2 (0.52) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL6655047 0.88 SMN1; SMN2 (0.43) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL6661188 0.86 KDM4E (0.50) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL6681449 0.86 KMT2A (0.44) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL6365239 0.86 AAK1 (0.49) PDE4APDE4BPDE4CPDE4DSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040235845-A1 Use of phosphodiesterase iv inhibitors MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2004-11-25 US disclosed
EP-1435958-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GmbH (DE) 2004-07-14 EP disclosed
WO-2003032993-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GMBH (DE) 2003-04-24 WO disclosed
EP-0763534-B1 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors MERCK PATENT GMBH (DE) 2003-02-26 EP disclosed
US-5859008-A Arylalkyl diazinones MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1999-01-12 US disclosed
EP-0763534-A1 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors MERCK PATENT GmbH (DE) 1997-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235845-A1 Use of phosphodiesterase iv inhibitors PDE4A, PDE3A, PDE3B PDE4A 1/4885PDE4B 4/4885PDE4C 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.